Papiol S, Mitjans M, Assogna F, Piras F, Hammer C, Caltagirone C, Arias B, Ehrenreich H, Spalletta G
1] Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany [2] DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany [3] Centro de Investigaciones Biomédicas en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
1] Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany [2] Centro de Investigaciones Biomédicas en Red de Salud Mental (CIBERSAM), Barcelona, Spain [3] Unitat Antropologia, Departament de Biologia Animal, Facultat de Biologia and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain.
Transl Psychiatry. 2014 Feb 18;4(2):e362. doi: 10.1038/tp.2013.126.
A recent publication reported an exciting polygenic effect of schizophrenia (SCZ) risk variants, identified by a large genome-wide association study (GWAS), on total brain and white matter volumes in schizophrenic patients and, even more prominently, in healthy subjects. The aim of the present work was to replicate and then potentially extend these findings. According to the original publication, polygenic risk scores-using single nucleotide polymorphism (SNP) information of SCZ GWAS-(polygenic SCZ risk scores; PSS) were calculated in 122 healthy subjects, enrolled in a structural magnetic resonance imaging (MRI) study. These scores were computed based on P-values and odds ratios available through the Psychiatric GWAS Consortium. In addition, polygenic white matter scores (PWM) were calculated, using the respective SNP subset in the original publication. None of the polygenic scores, either PSS or PWM, were found to be associated with total brain, white matter or gray matter volume in our replicate sample. Minor differences between the original and the present study that might have contributed to lack of reproducibility (but unlikely explain it fully), are number of subjects, ethnicity, age distribution, array technology, SNP imputation quality and MRI scanner type. In contrast to the original publication, our results do not reveal the slightest signal of association of the described sets of GWAS-identified SCZ risk variants with brain volumes in adults. Caution is indicated in interpreting studies building on polygenic risk scores without replication sample.
最近的一项出版物报道了一项令人兴奋的研究成果,即通过一项大型全基因组关联研究(GWAS)确定的精神分裂症(SCZ)风险变异对精神分裂症患者的全脑和白质体积有影响,在健康受试者中这种影响更为显著。本研究的目的是重复并可能扩展这些发现。根据原始出版物,在122名参与结构磁共振成像(MRI)研究的健康受试者中计算了多基因风险评分——使用SCZ GWAS的单核苷酸多态性(SNP)信息——(多基因SCZ风险评分;PSS)。这些评分是根据通过精神疾病GWAS联盟获得的P值和比值比计算得出的。此外,使用原始出版物中的相应SNP子集计算了多基因白质评分(PWM)。在我们的重复样本中,未发现任何多基因评分(PSS或PWM)与全脑、白质或灰质体积相关。原始研究和本研究之间可能导致缺乏可重复性的微小差异(但不太可能完全解释)包括受试者数量、种族、年龄分布、阵列技术、SNP填充质量和MRI扫描仪类型。与原始出版物不同,我们的结果并未揭示所描述的GWAS确定的SCZ风险变异集与成年人脑体积之间存在丝毫关联信号。在解释基于多基因风险评分且无重复样本的研究时需谨慎。